BBJ holds first-ever 'Summer Soiree at the Zoo' event (PHOTOS)
A gorilla is trained to allow for an oral exam as the 2025 Boston Business Journal Summer Soiree at the Zoo – Network & Connect, is held at Franklin Park Zoo.
Gary Higgins / Boston Business Journal
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Journals
5 hours ago
- Business Journals
Five things you need to know today, Woodstock, zoo photos and games people play (even me)
Good morning, Boston. Happy National Relaxation Day. Don't forget to nominate someone for the BBJ's Power 50 — nominations close on Sunday. Here are the five things you need to know in local business news to start your last day of the workweek. 1. Boston's only direct flight to Hawaii is discontinued Hawaiian Airlines is suspending its direct flight from Boston to Honolulu starting in November, Isabel Hart reports. GET TO KNOW YOUR CITY Find Local Events Near You Connect with a community of local professionals. Explore All Events 2. Former Bridj CEO to take AI aviation company public via SPAC Matt George, whose defunct-and-resurrected bus startup once dreamed of driverless vehicles, is now behind a company is building AI software to assist aircraft pilots — and it's planning to go public via a special purpose acquisition company, or SPAC, Lucia Maffei reports. 3. Mismanagement, inequities found at cannabis commission An audit of the state's cannabis regulatory agency found that mismanagement and a lack of internal controls at the commission resulted in violations of state regulations and procedural inequities, Isabel Hart reports. Sponsor this page! Want your brand aligned with the 5 Things You Need to Know? Contact Jill Cohen for more information and sponsorship opportunities. 4. Fired Market Basket execs ordered to stay away from stores Grant Welker reports that a Middlesex Superior Court judge issued an injunction on Thursday against two fired Market Basket employees, ordering them to stay away from the grocery chain's properties. 5. Lilly's latest billion-dollar-plus obesity deal The latest obesity bet from Eli Lilly and Co. involves a Boston biotech based out of the pharma giant's new Fort Point R&D center, Hannah Green reports. What else you need to know On the radio This morning at 6:45 or 8:45 on GBH Radio's "Morning Edition" listen for Jess Aloe's report, the "Boston Business Journal Minute," a quick highlight of the week's top stories. Not near the radio? Listen here. What's going on? The BBJ's first-ever 'Summer Soiree at the Zoo' event was a smash hit. Check out the photos. Today in history On August 15, 1969, the Woodstock Festival kicked off at Max Yasgur's farm in Bethel, New York. (On This Day In Music) (Scroll down for an AI-assisted walk down Memory Lane.) What's good on WERS-FM Dancing Barefoot, by Patti Smith Group What I'm watching The Goes Wrong Show, on Prime Games people play (even me) Happy Friday, everyone! I'm getting ready for a quick trip to Nashville to visit my son, but don't worry — I'll be back here in this space first thing Monday morning! Meanwhile, since I'll be spending some time with my son and future daughter-in-law and my wife, I am already preparing for the board games they will want to play. All of them are board-game lovers. I, on the other hand, am not a board-game lover. Whenever my son would come home from college, my family would make me play Settlers of Catan. I can tolerate that game. The one board game I do enjoy playing is called Wingspan, which I've mentioned in this space before, and which I recommend to people who like board games or who like birds but not to people who like neither board games nor birds. Are there other board games I'd try? That's a good question. The New York Times recently mentioned a game I'd consider — called Ticket to Ride — but only because it wrote specifically that Ticket to Ride is a board game for people who don't like board games. It's like they know me. According to the Times, it's simple to learn, quick to master and 'strategically plentiful.' The point of the game? Players race to position colorful trains along routes across North America — from Boston to New York, Omaha to Denver, Salt Lake City to San Francisco, etc. Seems simple and doesn't take hours to complete. I haven't played it yet, but if it's as good as the Times says it is, I would be open to giving it a try. As you think about what to do in your summer house these last few weeks before school starts again, maybe it's a game for you and your family too. PARTING SHOT Classic photos from Woodstock, taken by Henry Diltz were brought to life using AI: Subscribe to the Morning Edition or Afternoon Edition for the business news you need to know, all free. Largest Business Advocacy Organizations in Massachusetts Total revenue Rank Prior Rank Organization/Prior rank (*unranked in 2024)/ 1 1 Union of Concerned Scientists 2 2 MassBio 3 4 Massachusetts Health & Hospital Association View this list
Yahoo
7 hours ago
- Yahoo
Elutia Inc (ELUT) Q2 2025 Earnings Call Highlights: Strong EluPro Growth Amid Financial Challenges
BioEnvelope Revenue: Up 33% year over year, reaching a $14 million run rate. EluPro Growth: 49% sequential growth for the quarter, now comprising 68% of BioEnvelope revenue. Hospital Systems: 161 hospital systems actively ordering EluPro. Sales Performance: EluPro sales per account are 130% higher than CanGaroo. Distributor Network: 1,099 distributors, contributing 33% of total sales. Boston Scientific Partnership: Involved in 98 hospitals, facilitating 30% of EluPro cases. Total Quarterly Sales: $6.3 million for the quarter. Gross Margin: Adjusted gross margin at 62.4% for Q2, up over 4 percentage points from a year ago. Adjusted EBITDA: $3.8 million loss for the quarter. Cash Position: Ended Q2 with $8.5 million in cash. Warning! GuruFocus has detected 5 Warning Signs with ELUT. Release Date: August 14, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Elutia Inc (NASDAQ:ELUT) reported a 49% sequential growth in EluPro sales, driven by securing seven national GPO contracts and expanding into 161 hospital systems. The company has developed a strong partnership with Boston Scientific, which is actively involved in EluPro sales in 98 hospitals, facilitating 30% of EluPro cases. Elutia Inc (NASDAQ:ELUT) has achieved significant recognition for its drug-eluting technology, winning multiple awards including the Edison Award and Medical Device Network Excellence Awards. The company is making substantial progress in the breast reconstruction market with its NXT-41x platform, aiming to address significant unmet medical needs. Elutia Inc (NASDAQ:ELUT) has settled 97 out of 110 lawsuits related to a past product recall, reducing legal expenses and removing a significant overhang on the company. Negative Points Elutia Inc (NASDAQ:ELUT) faces challenges in scaling VAC approvals, which are crucial for revenue growth, with a current target of 1,600 hospital centers. The company is still dealing with 13 unresolved lawsuits from a past product recall, which continue to pose a potential financial and reputational risk. SimpliDerm sales have underperformed, generating $2 million in revenue, which is lower than previous quarters. Elutia Inc (NASDAQ:ELUT) reported a $3.8 million adjusted EBITDA loss for the quarter, indicating ongoing financial challenges despite revenue growth. The company has $8.5 million in cash, which may be insufficient for future growth initiatives without successful business development transactions. Q & A Highlights Q: What are the current bottlenecks for EluPro's growth, and how is Elutia addressing them? A: C. Randal Mills, CEO, explained that initially, the commercial team challenged the operations team to keep up with production, but they have since mastered it, as reflected in improved gross margins. The main focus now is scaling VAC approvals, as revenue growth is directly tied to the number of hospitals ordering EluPro. The company is targeting 1,600 centers and maintains a strong pipeline of VAC submissions, with Boston Scientific aiding in opening new accounts. Q: Can you provide more details on the NXT-41 development timeline and its relation to SimpliDerm? A: C. Randal Mills, CEO, stated that the NXT-41 platform will be launched in two phases: the base matrix in the second half of 2026 and the drug-eluting version in the first half of 2027. The base matrix is a new engineered product, not derived from SimpliDerm, designed to eliminate donor variability. SimpliDerm helps establish key accounts and relationships, but NXT-41 aims to offer a more complete solution. Q: How soon can we expect updates on business development activities? A: C. Randal Mills, CEO, mentioned that while nothing is finalized, they expect to conclude at least one transaction in the coming weeks or quarters. He emphasized the importance of not rushing the process to ensure quality outcomes. Q: What are the prospects for maintaining or expanding gross margins, especially with cardiovascular products back in the mix? A: Matthew Ferguson, CFO, highlighted opportunities for gross margin improvement across all segments. EluPro's scaling will enhance margins, cardiovascular products already have high margins over 80%, and there are efficiency improvements possible with SimpliDerm. Q: What level of clinical evidence is needed for FDA approval of NXT-41's base matrix and drug-eluting version? A: C. Randal Mills, CEO, explained that both versions will follow the same regulatory pathway as EluPro, involving the Center for Device and Radiologic Health and the Center for Drugs. The staggered launch allows for clinical data generation to support long-term success, with the base matrix proving its efficacy before adding the drug-eluting component. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Bloomberg
8 hours ago
- Bloomberg
True's New CEO Shifting Product Focus for Thai Telecom Leader
True Corp. Pcl plans to shift into higher-margin software services to leverage Thailand's largest mobile subscriber network that currently focuses on basic phone and WiFi connectivity, its new chief executive officer said. The telecom operator became No. 1 by total subscribers through the merger of two of Thailand's three biggest wireless operators – True and Total Access Communication Pcl – a deal finalized in March 2023. But the enlarged company is still 'basically just selling data connectivity,' said Group CEO Sigve Brekke, who took over in March after spending much of the past two decades holding senior roles at Total Access and Norway's Telenor ASA — now True's largest shareholder.
